Business Description
Compare
Compare
Traded in other countries / regions
51B.GermanyBVXP.UKBVNXF.USA Description
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, oncology, and vitamin D disorder.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.9 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 101.87 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.8 | |||||
| 3-Year EBITDA Growth Rate | 9.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.2 | |||||
| 3-Year FCF Growth Rate | 9 | |||||
| 3-Year Book Growth Rate | 2.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.12 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.69 | |||||
| 9-Day RSI | 49.9 | |||||
| 14-Day RSI | 51.11 | |||||
| 6-1 Month Momentum % | 18.52 | |||||
| 12-1 Month Momentum % | 23.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.44 | |||||
| Quick Ratio | 9.07 | |||||
| Cash Ratio | 4.89 | |||||
| Days Inventory | 200.32 | |||||
| Days Sales Outstanding | 54.04 | |||||
| Days Payable | 196.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.15 | |||||
| Dividend Payout Ratio | 0.78 | |||||
| 3-Year Dividend Growth Rate | 20 | |||||
| Forward Dividend Yield % | 3.15 | |||||
| 5-Year Yield-on-Cost % | 7.74 | |||||
| 3-Year Average Share Buyback Ratio | -0.4 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.92 | |||||
| Operating Margin % | 78.34 | |||||
| Net Margin % | 65.48 | |||||
| ROE % | 68.99 | |||||
| ROA % | 62.81 | |||||
| ROIC % | 137.86 | |||||
| ROC (Joel Greenblatt) % | 490.9 | |||||
| ROCE % | 82.95 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.31 | |||||
| Forward PE Ratio | 25.58 | |||||
| PE Ratio without NRI | 27.42 | |||||
| Shiller PE Ratio | 39.34 | |||||
| Price-to-Owner-Earnings | 24.32 | |||||
| PEG Ratio | 3.08 | |||||
| PS Ratio | 18.53 | |||||
| PB Ratio | 18.2 | |||||
| Price-to-Tangible-Book | 18.19 | |||||
| Price-to-Free-Cash-Flow | 28.8 | |||||
| Price-to-Operating-Cash-Flow | 28.74 | |||||
| EV-to-EBIT | 22.56 | |||||
| EV-to-Forward-EBIT | 19.85 | |||||
| EV-to-EBITDA | 22.21 | |||||
| EV-to-Forward-EBITDA | 19.66 | |||||
| EV-to-Revenue | 17.86 | |||||
| EV-to-Forward-Revenue | 15.82 | |||||
| EV-to-FCF | 26.84 | |||||
| Price-to-Projected-FCF | 2.33 | |||||
| Price-to-DCF (Earnings Based) | 0.82 | |||||
| Price-to-DCF (FCF Based) | 0.84 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.17 | |||||
| Price-to-Graham-Number | 4.79 | |||||
| Price-to-Net-Current-Asset-Value | 20.45 | |||||
| Price-to-Net-Cash | 44.41 | |||||
| Earnings Yield (Greenblatt) % | 4.43 | |||||
| Forward Rate of Return (Yacktman) % | 11.85 |
How Bioventix PLC (LSE:BVXP) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Details
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 11.72 | ||
| EPS (TTM) (£) | 1.459 | ||
| Beta | 0.24 | ||
| Volatility % | 21.97 | ||
| 14-Day RSI | 51.11 | ||
| 14-Day ATR (£) | 1.084959 | ||
| 20-Day SMA (£) | 40.58 | ||
| 12-1 Month Momentum % | 23.46 | ||
| 52-Week Range (£) | 28.8 - 43 | ||
| Shares Outstanding (Mil) | 5.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioventix PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioventix PLC Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||